NCT05577819Recruiting
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Prevalence and Prediction of Transthyretin Amyloidosis in Ambulatory Patients With Heart Failure With Preserved Ejection Fraction
Source: ClinicalTrials.gov · Last updated 1 Sept 2026
Brief summary (registry, in English)
Recent studies have shown that transthyretin amyloidosis (ATTR) can sometimes cause a type of heart failure where the pumping function of the heart is normal, also known as Heart Failure with Preserved Ejection Fraction (HFpEF) or diastolic heart failure. In this single center diagnostic study, we will evaluate for ATTR in patients with HFpEF in order to to determine how frequently this occurs and how we can predict which heart failure patients may have TTR amyloidosis. Our goal is to identify amyloidosis in heart failure patients earlier so that they can start treatment.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 515 (estimated)
- First submitted
- 16 Jul 2021
- Start date
- 2 Oct 2020
- Primary completion date
- 17 Jul 2026
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Amyloidosis, Heart failure
- NCT number
- NCT05577819
What you commit to
- Study type: Interventional
- Planned participants: 515
- From 2 Oct 2020 to the primary completion date, 17 Jul 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe valvular heart disease that is uncorrected (moderate to severe is considered exclusionary)
Lab values
- End stage chronic kidney disease on dialysis (CKD stage 5 as defined as eGFR \<15mL/min)
- no history of HFrEF (LVEF\<40%) with the exception of low LVEF in the setting of acute decompensation, AF RVR, ACS/MI, etc
Other
- Negative 99mTc-pyrophosphate scan within a year
- Unable to lie down for 15 minutes for the 99mTc-pyrophosphate scan
- Known diagnosis of amyloidosis
Who the study is looking for
- Patients with a confirmed diagnosis of HFpEF.
- Age ≥65 years old
Age in the registry: 65 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Massachusetts General Hospital Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.